Impact of Lymphocyte and Neutrophil Counts on Mortality Risk in Severe Community-Acquired Pneumonia with or without Septic Shock.

community-acquired pneumonia leukocyte subclasses counts lymphocytes mortality risk neutrophils

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
27 May 2019
Historique:
received: 03 04 2019
revised: 20 05 2019
accepted: 23 05 2019
entrez: 30 5 2019
pubmed: 30 5 2019
medline: 30 5 2019
Statut: epublish

Résumé

Community-acquired pneumonia (CAP) is a frequent cause of death worldwide. As recently described, CAP shows different biological endotypes. Improving characterization of these endotypes is needed to optimize individualized treatment of this disease. The potential value of the leukogram to assist prognosis in severe CAP has not been previously addressed. A cohort of 710 patients with CAP admitted to the intensive care units (ICUs) at Hospital of Mataró and Parc Taulí Hospital of Sabadell was retrospectively analyzed. Patients were split in those with septic shock ( Multivariate analysis demonstrated that lymphopenia <675 cells/mm lymphopenia is a preserved risk factor for mortality across the different clinical presentations of severe CAP (sCAP), while failing to expand circulating neutrophils counts beyond the upper limit of normality represents an incremental immunological failure observed just in those patients with the most severe form of CAP, septic shock.

Sections du résumé

BACKGROUND BACKGROUND
Community-acquired pneumonia (CAP) is a frequent cause of death worldwide. As recently described, CAP shows different biological endotypes. Improving characterization of these endotypes is needed to optimize individualized treatment of this disease. The potential value of the leukogram to assist prognosis in severe CAP has not been previously addressed.
METHODS METHODS
A cohort of 710 patients with CAP admitted to the intensive care units (ICUs) at Hospital of Mataró and Parc Taulí Hospital of Sabadell was retrospectively analyzed. Patients were split in those with septic shock (
RESULTS RESULTS
Multivariate analysis demonstrated that lymphopenia <675 cells/mm
CONCLUSION CONCLUSIONS
lymphopenia is a preserved risk factor for mortality across the different clinical presentations of severe CAP (sCAP), while failing to expand circulating neutrophils counts beyond the upper limit of normality represents an incremental immunological failure observed just in those patients with the most severe form of CAP, septic shock.

Identifiants

pubmed: 31137863
pii: jcm8050754
doi: 10.3390/jcm8050754
pmc: PMC6572378
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Chest. 2000 Feb;117(2):503-12
pubmed: 10669697
Eur Respir J. 2000 Apr;15(4):757-63
pubmed: 10780770
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
J Clin Pathol. 2004 Sep;57(9):950-5
pubmed: 15333656
Chest. 2005 Apr;127(4):1260-70
pubmed: 15821203
Arch Bronconeumol. 2005 May;41(5):272-89
pubmed: 15919009
Intern Med J. 2006 Jun;36(6):385-8
pubmed: 16732866
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Crit Care Med. 2007 Jun;35(6):1477-83
pubmed: 17440421
Crit Care Med. 2009 Feb;37(2):456-62
pubmed: 19114916
Crit Care Med. 2009 Nov;37(11):2867-74
pubmed: 19770748
Int J Lab Hematol. 2010 Dec;32(6 Pt 2):590-7
pubmed: 20236184
Crit Care. 2010;14(5):R192
pubmed: 21034463
Acad Emerg Med. 2012 Mar;19(3):294-303
pubmed: 22435862
PLoS One. 2012;7(10):e46561
pubmed: 23049706
Mediators Inflamm. 2013;2013:152943
pubmed: 24082429
Crit Care. 2014 Feb 14;18(1):407
pubmed: 24524810
Am J Emerg Med. 2014 Dec;32(12):1476-80
pubmed: 25264245
Infect Chemother. 2015 Mar;47(1):12-26
pubmed: 25844259
Crit Care. 2015 Feb 25;19:57
pubmed: 25887201
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
Med Clin (Barc). 2016 Aug 19;147(4):139-43
pubmed: 27237363
Int J Mol Sci. 2017 Feb 11;18(2):
pubmed: 28208675
PLoS One. 2017 Mar 16;12(3):e0173947
pubmed: 28301543
J Am Geriatr Soc. 2017 Aug;65(8):1796-1801
pubmed: 28407209
Ann Surg. 2019 Mar;269(3):545-553
pubmed: 28692472
Lancet Respir Med. 2017 Oct;5(10):816-826
pubmed: 28864056
EBioMedicine. 2017 Oct;24:231-236
pubmed: 28958655
Intensive Care Med Exp. 2017 Oct 23;5(1):49
pubmed: 29063386
Lancet Respir Med. 2017 Dec;5(12):e35-e36
pubmed: 29185421
Am J Respir Crit Care Med. 2018 Jul 15;198(2):256-263
pubmed: 29546996
Sci Rep. 2018 Mar 28;8(1):5301
pubmed: 29593221
Crit Care Med. 1981 Aug;9(8):591-7
pubmed: 7261642
JAMA. 1996 Jan 10;275(2):134-41
pubmed: 8531309
N Engl J Med. 1997 Jan 23;336(4):243-50
pubmed: 8995086

Auteurs

Estel Güell (E)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. estelguell@gmail.com.
Grup d'Estudi al Maresme de la Pneumònia Adquirida a la Comunitat (GEMPAC) acreditat per la AGAUR (expedient 2014 SGR 1018), Consorci Sanitari del Maresme, 08204 Mataró, Spain. estelguell@gmail.com.
Programa de Doctorat en Medicina de la Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebrón 119-129, 08035 Barcelona, Spain. estelguell@gmail.com.

Marta Martín-Fernandez (M)

Laboratory of Biomedical Research in Sepsis (BioSepsis), Hospital Clínico Universitario de Valladolid, Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain. mmartin.iecscyl@saludcastillayleon.es.

Mari C De la Torre (MC)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. mctorre@csdm.cat.
Grup d'Estudi al Maresme de la Pneumònia Adquirida a la Comunitat (GEMPAC) acreditat per la AGAUR (expedient 2014 SGR 1018), Consorci Sanitari del Maresme, 08204 Mataró, Spain. mctorre@csdm.cat.

Elisabet Palomera (E)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. epalomera@csdm.cat.
Grup d'Estudi al Maresme de la Pneumònia Adquirida a la Comunitat (GEMPAC) acreditat per la AGAUR (expedient 2014 SGR 1018), Consorci Sanitari del Maresme, 08204 Mataró, Spain. epalomera@csdm.cat.

Mateu Serra (M)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. mserra@csdm.cat.

Rafael Martinez (R)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. rmartinez@csdm.cat.

Manel Solsona (M)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. msolsona@csdm.cat.

Gloria Miró (G)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. gmiro@csdm.cat.

Jordi Vallès (J)

Intensive Care Medicine, Hospital Parc Taulí-Sabadell, 08208 Sabadell, Spain. jvalles@tauli.cat.

Samuel Fernández (S)

Intensive Care Medicine, Hospital Parc Taulí-Sabadell, 08208 Sabadell, Spain. sfernandezv@tauli.cat.

Edgar Cortés (E)

Intensive Care Medicine, Hospital Parc Taulí-Sabadell, 08208 Sabadell, Spain. ecortess@tauli.cat.

Vanessa Ferrer (V)

Intensive Care Medicine, Hospital Parc Taulí-Sabadell, 08208 Sabadell, Spain. vferrer@tauli.cat.

Marc Morales (M)

Intensive Care Medicine, Hospital Parc Taulí-Sabadell, 08208 Sabadell, Spain. marcmoralescodina@gmail.com.

Juan C Yébenes (JC)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. jcyebenes@csdm.cat.

Jordi Almirall (J)

Department of Intensive Care Medicine, Hospital de Mataró, Universitat Autònoma de Barcelona, 08304 Barcelona, Spain. jalmirall@csdm.cat.
Centro de Investigación Biomedica En Red-Enfermedades Respiratorias (CibeRes, CB06/06/0028), Instituto de salud Carlos III (ISCIII), Av. de Monforte de Lemos, 5, 28029 Madrid, Spain. jalmirall@csdm.cat.
Grup d'Estudi al Maresme de la Pneumònia Adquirida a la Comunitat (GEMPAC) acreditat per la AGAUR (expedient 2014 SGR 1018), Consorci Sanitari del Maresme, 08204 Mataró, Spain. jalmirall@csdm.cat.

Jesús F Bermejo-Martin (JF)

Laboratory of Biomedical Research in Sepsis (BioSepsis), Hospital Clínico Universitario de Valladolid, Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain. jfbermejo@saludcastillayleon.es.
Centro de Investigación Biomedica En Red-Enfermedades Respiratorias (CibeRes, CB06/06/0028), Instituto de salud Carlos III (ISCIII), Av. de Monforte de Lemos, 5, 28029 Madrid, Spain. jfbermejo@saludcastillayleon.es.

Classifications MeSH